Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has issued an update.
Paradigm Biopharmaceuticals has disclosed a change in the interests of director Paul Rennie, who has converted 153,265 listed options into fully paid ordinary shares. The transaction, executed on 3 February 2026 for a consideration of $99,622.25, increases Rennie’s direct holding of ordinary shares while reducing his listed options by the same amount, signalling a shift from derivative exposure to outright equity ownership and marginally strengthening insider alignment with ordinary shareholders.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian listed biotechnology company focused on developing and commercialising biopharmaceutical therapies. The company operates in the life sciences sector and its securities, including fully paid ordinary shares, listed options and performance rights, are traded on the ASX, attracting both retail and institutional investors interested in healthcare and biotech exposure.
Average Trading Volume: 902,057
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$132.2M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.